Amôr, Nádia Ghinelli 
; Oliveira, Carine Ervolino de; Gasparoto, Thaís Helena ; Vilas Boas, Vanessa Garcia ; Perri, Graziela ; Kaneno, Ramon; Lara, Vanessa Soares ; Garlet, Gustavo Pompermaier ; Silva, João Santana da ; Martins, Gislaine Aparecida; Hogaboam, Cory ; Cavassani, Karen Angelica; Campanelli, Ana Paula
Source: Oncotarget. Unidades: FOB, FMRP
Subjects: CARCINOMA DE CÉLULAS ESCAMOSAS, CAMUNDONGOS, INTERLEUCINAS, CARCINÓGENOS QUÍMICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AMÔR, Nádia Ghinelli et al. ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate. Oncotarget, v. 9, n. 56, p. 30894-30904, 2018Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.30894. Acesso em: 14 out. 2024.APA
Amôr, N. G., Oliveira, C. E. de, Gasparoto, T. H., Vilas Boas, V. G., Perri, G., Kaneno, R., et al. (2018). ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate. Oncotarget, 9( 56), 30894-30904. doi:10.18632/oncotarget.30894NLM
Amôr NG, Oliveira CE de, Gasparoto TH, Vilas Boas VG, Perri G, Kaneno R, Lara VS, Garlet GP, Silva JS da, Martins GA, Hogaboam C, Cavassani KA, Campanelli AP. ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate [Internet]. Oncotarget. 2018 ; 9( 56): 30894-30904.[citado 2024 out. 14 ] Available from: https://doi.org/10.18632/oncotarget.30894Vancouver
Amôr NG, Oliveira CE de, Gasparoto TH, Vilas Boas VG, Perri G, Kaneno R, Lara VS, Garlet GP, Silva JS da, Martins GA, Hogaboam C, Cavassani KA, Campanelli AP. ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate [Internet]. Oncotarget. 2018 ; 9( 56): 30894-30904.[citado 2024 out. 14 ] Available from: https://doi.org/10.18632/oncotarget.30894
